Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2, 2007. The report details a share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 2,750,000 Ordinary shares.
- Purchase Price: 1,274.11 pence per share.
- Purchase Date: August 2, 2007.
- Treasury Holdings: 336,199,158 shares (representing 5.91% of total voting rights).
- Shares in Issue: 5,685,334,641 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares and the increase in Treasury stock following the repurchase of 2,750,000 shares. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of specific risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,685,334,641) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (336,199,158) and its impact on total voting rights (5.91%).
- Review the Annual General Meeting minutes from May 23, 2007, to confirm the scope of the share repurchase authority utilized.